[Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Fabreegas
Bernadette
B
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism / Q000451:nursing; D003927:Diet, Diabetic; D004359:Drug Therapy, Combination; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives*; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D054795:Incretins / Q000502:physiology*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D010353:Patient Education as Topic; D018579:Patient Selection; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use*; D014688:Venoms / Q000494:pharmacology / Q000627:therapeutic use*
D007004:Hypoglycemic Agents; D054795:Incretins; D007328:Insulin; D010455:Peptides; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D008687:Metformin; D000077270:Exenatide